Loss of PTEN Expression in Neuroendocrine Pancreatic Tumors

M. Krausch; A. Raffel; M. Anlauf; M. Schott; H. Willenberg; N. Lehwald; D. Hafner; K. Cupisti; C. F. Eisenberger; W. T. Knoefel

doi:10.1055/s-0031-1291333

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 2011; 43(12): 865-871
DOI: 10.1055/s-0031-1291333

Humans, Clinical

Loss of PTEN Expression in Neuroendocrine Pancreatic Tumors

M. Krausch^*

¹Department of General, Visceral and Pediatric Surgery, , Heinrich-Heine University of Düsseldorf, Germany

,

A. Raffel^*

¹Department of General, Visceral and Pediatric Surgery, , Heinrich-Heine University of Düsseldorf, Germany

,

M. Anlauf

²Institute of Pathology, Heinrich-Heine University of Düsseldorf, Germany

,

M. Schott

³Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine University of Düsseldorf, Germany

,

H. Willenberg

³Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine University of Düsseldorf, Germany

,

N. Lehwald

¹Department of General, Visceral and Pediatric Surgery, , Heinrich-Heine University of Düsseldorf, Germany

,

D. Hafner

⁴Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine University of Düsseldorf, Germany

,

K. Cupisti

¹Department of General, Visceral and Pediatric Surgery, , Heinrich-Heine University of Düsseldorf, Germany

,

C. F. Eisenberger

¹Department of General, Visceral and Pediatric Surgery, , Heinrich-Heine University of Düsseldorf, Germany

,

W. T. Knoefel

¹Department of General, Visceral and Pediatric Surgery, , Heinrich-Heine University of Düsseldorf, Germany

› Institutsangaben

Abstract

PTEN (phosphatase and tensin homologue deleted from chromosome 10) is a well established tumor suppressor gene, which was cloned to chromosome 10q23. PTEN plays an important role in controlling cell growth, apoptosis, cell adhesion, and cell migration. In various studies, a genetic change as well as loss of PTEN expression by different carcinomas has been described. To date, the role of PTEN as a differentiation marker for neuroendocrine tumors (NET) and for the loss of PTEN expression is still unknown. It is assumed that loss of PTEN expression is important for tumor progression of NETs. We hypothesize that PTEN might be used as a new prognostic marker. We report 38 patients with a NET of the pancreas. Tumor tissues were surgically resected, fixed in formalin, and embedded in paraffin. PTEN expression was evaluated by immunohistochemistry and was correlated with several clinical and pathological parameters of each individual tumor. After evaluation of our immunohistochemistry data using a modified Remmele Score, a widely accepted method for categorizing staining results for reports and statistical evaluation, staining results of PTEN expression were correlated with the clinical and pathological parameters of each individual tumor. Our data demonstrates a significant difference in survival with existence of lymph node or distant metastases. Negative patients show a significant better survival compared with positive patients. Furthermore, we show a significant difference between PTEN expression and WHO or TNM classification. Taken together, our data shows a positive correlation between WHO classification and the new TNM classification of NETs, and loss of PTEN expression as well as survival. These results strongly implicate that PTEN might be helpful as a new prognostic factor.

Key words

PTEN - neuroendocrine pancreatic tumors - prognostic marker

Volltext

Referenzen

References
1 Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. PTEN a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-1947
2 Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997; 57: 2124-2129
3 Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1007; 15: 356-362
4 Zhao H, Dupont J, Yakar S, Karas M, LeRoith D. PTEN inhibits egulating cell proliferation and induces apoptosis by downrcell surface IGF-IR expression in prostate cancer cells. Oncogene 2004; 23: 786-794
5 Konopka B, Janiec-Jankowska A, Paszko Z, Goluda M. The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma. J Cancer Res Clin Oncol 2004; 130: 114-121
6 Brown KS, Blair D, Reid SD, Nicholson EK, Harnett MM. FcgammaRIIb-mediated negative regulation of BCR signalling is associated with the recruitment of the MAPKinasephosphatase, Pac-1, and the 3′-inositol phosphatase, PTEN. Cell Signal 2004; 16: 71-80
7 Cho SH, Lee CH, Ahn Y, Kim H, Kim H, Ahn CY, Yang KS, Lee SR. Redox regulation of PTEN and protein tyrosine phosphatases in H(2)O(2) mediated cell signaling. FEBS Lett 2004; 560: 7-13
8 Wishart MJ, Dixon JE. PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease. Trends Cell Biol 2002; 12: 579-585
9 Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol 2003; 30 (Suppl. 16) 93-104
10 Orchiston EA, Bennett D, Leslie NR, Clarke RG, Winward L, Downes CP Safrany ST PTEN M-CBR3 a versatile and selective regulator of inositol 1,3,4,5,6-pentakisphosphate (Ins (1,3,4,5,6) P5). Evidence for Ins (1,3,4,5,6)P5 as a proliferative signal. J Biol Chem 2004; 279: 1116-1122
11 Wang L, Ignat A, Axiotis CA. Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl Immunohistochem Mol Morphol 2002; 10: 139-146
12 Li XH, Zheng HC, Takahashi H, Masuda S, Yang XH, Takano Y. PTEN expression and mutation in colorectal carcinomas. Oncol Rep 2009; 22: 757-764
13 Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz Jr LA, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N. DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors. Science 2011; 331 (6021) 1199-1203
14 Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, Heitz PU, Eng C. Mutation and expression analysis reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 2000; 157: 1097-1103
15 Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B. and all other Frascati Consensus Conference participants; European Neuroendocrine Tumor Society (ENETS) . TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401
16 McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics . Reporting recommendations for tumor marker prognostic studies (remark). Exp Oncol 2006; 28: 99-105
17 Lohmann DR, Funk A, Niedermeyer HP, Haupel S, Hofler H. Identification of p53 gene mutations in gastrointestinal and pancreatic carcinoids by nonradioisotopic SSCA. Virchows Arch B Cell Pathol 1993; 64: 293-296
18 Hofler H, Ruhri C, Putz B, Wirnsberger G, Hauser H. Oncogene expression in endocrine pancreatic tumors. Virchows Arch B Cell Pathol 1988; 55: 355-361
19 Speel EJ, Richter J, Moch H, Egenter C, Saremaslani P, Rutimann K, Zhao J, Barghorn A, Roth J, Heitz PU, Komminoth P. Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am J Pathol 1999; 155: 1787-1794
20 O’Connor R. Regulation of IGF-I receptor signaling in tumor cells. Horm Metab Res 2003; 35: 771-777
21 Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999; 96: 1563-1568
22 Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, Fukumoto M, Mak TW. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998; 8: 1169-1178
23 Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN Testa JR AKT2 a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992; 89: 9267-9271
24 Boehle AS, Kurdow R, Boenicke L, Schniewind B, Faendrich F, Dohrmann P, Kalthoff H. Wortmannin inhibits growth of human non-small-cell lung cancer in vitro and in vivo. Langenbecks Arch Surg 2002; 387: 234-239
25 Lee SR, Yang KS, Kwon J, Lee C, Jeong W, Rhee SG. Reversible inactivation of the tumor suppressor PTEN by H₂O₂ . J Biol Chem 2002; 277: 20336-20342
26 Gericke A, Munson M, Ross AH. Regulation of the PTEN phosphatase. Gene 2006; 374: 1-9
27 Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G, Pederzoli P, Croce CM, Scarpa A. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010; 28: 245-255
28 Liliental J, Moon SY, Lesche R, Mamillapalli R, Li D, Zheng Y, Sun H, Wu H. Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr Biol 2000; 10: 401-404
29 Suzuki A, Kaisho T, Ohishi M, Tsukio-Yamaguchi M, Tsubata T, Koni PA, Sasaki T, Mak TW, Nakano T. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J Exp Med 2003; 197: 657-667
30 Suzuki A, Kaishu T, Ohishi M, Tsukio-Yamaguchi M, Tsubata T, Koni PA, Sasaki T, Mak TW, Nakano T. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J Exp Med 2003; 197: 657-667
31 Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998; 280: 1614-1617
32 Lacalle RA, Gomez-Mouton C, Barber DF, Jimenez-Baranda S, Mira E, Martinez AC, Carrera AC, Manes S. PTEN regulates motility but not directionality during leukocyte chemotaxis. J Cell Sci 2004; 117: 6207-6215
33 Sanchez T, Thangada S, Wu MT, Kontos CD, Wu D, Wu H, Hla T. PTEN as an effector in the signaling of antimigratory G protein-coupled receptor. Proc Natl Acad Sci USA 2005; 102: 4312-4317
34 Chalhoub N, Baker JS. PTEN and the PI3-Kinase Pathway in Cancer. Annu Rev Pathol Mech Dis 2009; 4: 127-150
35 Jiang BH, Liu LZ. PI3K/PTEN signalling in angiogenesis and tumoroginesis. Adv Cancer Res 2009; 102: 19-65
36 Sawai H, Yasuda A, Ochi N, Ma J, Matsuo Y, Wakasugi T, Takahashi H, Funahashi H, Sato M, Takeyama H. Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival. BMC Gastroenterology 2008; 8: 56
37 Bardelli A, Pierotti MA. Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res 2005; 65: 11227
38 Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cance 2007; 97: 1139-1145
39 Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Soler RP, Mariadason JM. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008; 68: 1953-1961
40 Jang K-S, Song YS, Jang S-H, Min K-W, Na W, Jang SM, Jun YJ, Lee KH, Choi D, Paik SS. Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology 2010; 56: 229-239
41 O’Toole D, Couvelard A, Rebours V, Zappa M, Hentic O, Hammel P, Levy P, Bedossa P, Raymond E, Ruszniewski P. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. Endocr Relat Cancer 2010; 17: 847-856